Kohesio: discover EU projects in your region

project info
Start date: 1 February 2017
End date: 31 March 2022
funding
Fund: European Regional Development Fund (ERDF)
Total budget: 796 945,52 €
EU contribution: 488 320,47 € (61,27%)
programme
Programming period: 2014-2020
Managing authority: Zarząd Województwa obsługiwany przez Urząd Marszałkowski
© Lublin Agency for Entrepreneurship Support
© Lublin Agency for Entrepreneurship Support

Clinical studies of bone replacement biocomposite FlexiOss “artificial bone”

The aim of the project is to conduct clinical trials of an invention of the international scale of innovation of the bone replacement biomaterial. “artificial bone” [patent protection in Poland “Bioactive Composite and Bioactive Composite” (UPRP decision of 5 March 2010, WYN: (11) 206394) as well as in European countries: Austria, Spain, Italy, Switzerland, Germany, France, England, Ireland (“Bioactive composite and process for the production of the bioactive composite”; European patent No 2421570 B1; issued in September 2014, published on 25.02.2015] and the start of research into new material functionally complementary to the biocomposit. The church biomaterial was highly rated at the International Fair of Invention in Brussels in 2013 and received the Medal for Best Invention developed by Women Inventor, Grand Prix and Gold Medal with distinction. The Medical Inventi composite is characterised by the following innovative features: >> Application to its production of synthetic hydroxyapatite granules with very high ion reactivity. This feature allows very rapid capture of calcium and phosphorus ions from tissue fluids and significantly increased – compared to standard hydroxyapatites available on the market – deposition of biological apatite, which accelerates bone opening process; >> High elasticity and plasticity (after soaked in the blood or solution of the medicine) thanks to the polymer phase, which allows the composite to obtain a high surgical suitability and adjust it to the dimensions of the completed bone loss; >> minimise the risk of viral contamination by using a bacterial polymer (this risk is relatively high for many commercial biomaterials based on animal collagen). Following the implementation of the project, the invention will be fully commercialised.

Flag of Poland  Lubelski, Poland